Literature DB >> 16036098

Glucocorticoid-induced osteoporosis: treatment options and guidelines.

Michael Maricic1.   

Abstract

Glucocorticoid-induced osteoporosis and fractures are the most frequent adverse effects of this class of medication. Recent advances in the pathophysiology, epidemiology, detection, and prevention of this complication of therapy provide hope for its amelioration in patients who require treatment with glucocorticoids. A number of effective pharmacologic agents are available and/or under study, and scientific organizations now provide guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Unfortunately, consistent application of these guidelines remains suboptimal in many practice settings.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16036098     DOI： 10.1007/s11914-005-0024-8

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


  31 in total

1.  Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice.

Authors:  Daniel H Solomon; Jeffrey N Katz; Jonathan P Jacobs; Alison M La Tourette; Jonathan Coblyn
Journal:  Arthritis Rheum       Date:  2002-12

2.  Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.

Authors:  N E Lane; S Sanchez; G W Modin; H K Genant; E Pierini; C D Arnaud
Journal:  J Bone Miner Res       Date:  2000-05       Impact factor: 6.741

Review 3.  The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.

Authors:  S Amin; M P LaValley; R W Simms; D T Felson
Journal:  Arthritis Rheum       Date:  1999-08

4.  Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Authors:  S Cohen; R M Levy; M Keller; E Boling; R D Emkey; M Greenwald; T M Zizic; S Wallach; K L Sewell; B P Lukert; D W Axelrod; A A Chines
Journal:  Arthritis Rheum       Date:  1999-11

Review 5.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

6.  A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Authors:  J H Healey; S A Paget; P Williams-Russo; T P Szatrowski; R Schneider; H Spiera; H Mitnick; K Ales; P Schwartzberg
Journal:  Calcif Tissue Int       Date:  1996-02       Impact factor: 4.333

7.  The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Authors:  Shreyasee Amin; Michael P Lavalley; Robert W Simms; David T Felson
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

8.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

Authors:  K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

9.  Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

Authors:  K G Saag; R Emkey; T J Schnitzer; J P Brown; F Hawkins; S Goemaere; G Thamsborg; U A Liberman; P D Delmas; M P Malice; M Czachur; A G Daifotis
Journal:  N Engl J Med       Date:  1998-07-30       Impact factor: 91.245

10.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507
View more
  2 in total

Review 1.  Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.

Authors:  Paul D Miller
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

2.  Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss.

Authors:  Takuo Kubota; Noriyuki Namba; Shunji Kurotobi; Shigetoyo Kogaki; Haruhiko Hirai; Taichi Kitaoka; Shigeo Nakajima; Keiichi Ozono
Journal:  Clin Pediatr Endocrinol       Date:  2006-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.